Blue Jet Healthcare announces Q1 FY27 results and key leadership/auditor appointments
Blue Jet Healthcare · Pharmaceuticals & Biotechnology
Key highlights
- Q1 FY27 unaudited revenue from operations was ₹293.11 crore; profit after tax ₹78.26 crore
- Re-appoint Mr. Akshay Bansarilal Arora as Executive Chairman for 5 years from April 13, 2027
- Re-appoint Mr. Shiven Akshay Arora as Managing Director for 5 years from April 13, 2027
Why it's rated notable: the year-on-year change is 14% (10% to 20% for adverse news)
Figures checked against the filing by a second AI read. About the business, not the share price.
Original filing
Outcome Of Board Meeting For Unaudited Standalone Financial Results Of The Company For The First Quarter Ended June 30, 2026.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Blue Jet Healthcare
- Fundraise / allotmentMajor developmentBlue Jet Healthcare Limited announces Q2 and H1 FY2027 unaudited financial results
- Financial resultsMajor developmentBlue Jet Healthcare announces unaudited results for quarter ended September 30, 2026
- Board / shareholder meeting outcomeNotable· Adverse for the businessBlue Jet Healthcare Q1 profit ₹782.64 million; re-appointments await AGM approval
- Fundraise / allotmentNotable· Adverse for the businessBlue Jet Healthcare Limited announces Q1 FY2026-27 results and re-appointments
- Fundraise / allotmentNotable· Adverse for the businessBlue Jet Healthcare approves Q1 FY 2026-27 results and reappointments of key leaders and auditors
Other financial results filings this fortnight
- Siddhika Coatings Limited approves joint venture and announces H1 FY 2026 financials
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2026 unaudited financial results
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2027 financial results and divestment
- NHC Foods reports Sept 2026 quarter results, 99.98% firm stake, two appointments
- Spectrum Electrical Industries Ltd approves Q2 & H1 results for period ended September 30, 2026
- Dev Labtech Venture reports unaudited half-year results to 30 Sept 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.